MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD DisclosureITEM 7.01
REGULATION FD DISCLOSURE
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
On March 6, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release that stated the Company received a letter from the Listing Qualifications Department of The NASDAQ Capital Market notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) as a result of maintaining the $1.00 minimum closing bid price for at least ten trading days prior to the March 5, 2018, deadline for continued listing. The press release is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Press release issued March 6, 2018 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 Exhibit 99.1 MabVax Therapeutics Regains Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement SAN DIEGO,…To view the full exhibit click here
